Coronavirus Update: J&J Shows Promise Against Omicron, UK Nod For Paxlovid
Plus Comirnaty Touted For Teens
• By Scrip Team
Generate a summary of this article
Listen to this article
The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.
The Sisonke Study Was Conducted By The South African Medical Research Council. • Source: Alamy
Johnson & Johnson’s COVID-19 vaccine booster has demonstrated 85% effectiveness against COVID-19-related hospitalization according to preliminary data from a study by the South African Medical Research Council.
The Phase IIIb Sisonke trial showed the booster shot reduced the risk of hospitalization from COVID-19 in South African healthcare...
Keep up with the top pharma business news of the week. On the go.
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.